Dibenzoylmethane

Dibenzoylmethane

SCHEMBL1930339

F[B]F.O=C(CC(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.81
▸ MEN1 O00255 4/20 0.81
▸ HPGD P15428 4/20 0.81
▸ MAPT P10636 4/20 0.81
▸ MAPK1 P28482 3/20 0.81
▸ SMN1; SMN2 Q16637 3/20 0.81
▸ CYP3A4 P08684 2/20 0.81
▸ TDP1 Q9NUW8 2/20 0.81
▸ ALOX15 P16050 2/20 0.81
▸ KDM4E B2RXH2 1/20 0.81
▸ CES1 P23141 1/20 0.81
▸ NPC1 O15118 5/20 0.63
▸ RAB9A P51151 4/20 0.63
▸ PLOD2 O00469 2/20 0.63
▸ ALDH1A1 P00352 2/20 0.63
▸ HIF1A Q16665 2/20 0.63
▸ PLOD3 O60568 1/20 0.63
▸ CYP1A2 P05177 1/20 0.63
▸ CYP2D6 P10635 1/20 0.63
▸ CYP2C9 P11712 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dibenzoylmethane SCHEMBL39582 0.90 MEN1 (1.00) KMT2AMEN1HPGDMAPTMAPK1
Dibenzoylmethane SCHEMBL10356288 0.90 MEN1 (1.00) KMT2AMEN1HPGDMAPTMAPK1
Dibenzoylmethane SCHEMBL1704711 0.90 MEN1 (1.00) KMT2AMEN1HPGDMAPTMAPK1
SCHEMBL28972855 0.90 KMT2A (0.65) KMT2AMEN1HPGDMAPTMAPK1
SCHEMBL28972880 0.90 MEN1 (0.65) KMT2AMEN1HPGDMAPTMAPK1
Dibenzoylmethane SCHEMBL28463188 0.88 KMT2A (0.85) KMT2AMEN1HPGDMAPTMAPK1
Dibenzoylmethane SCHEMBL11587518 0.87 MEN1 (0.94) KMT2AMEN1HPGDMAPTMAPK1
Dibenzoylmethane SCHEMBL9276614 0.87 MEN1 (0.94) KMT2AMEN1HPGDMAPTMAPK1
Dibenzoylmethane SCHEMBL11909772 0.87 MEN1 (0.94) KMT2AMEN1HPGDMAPTMAPK1
Dibenzoylmethane SCHEMBL21597905 0.87 MEN1 (0.94) KMT2AMEN1HPGDMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114307890-B Bamboo capsule and preparation method and application thereof 中国林业科学研究院木材工业研究所 2022-12-23 — — CN claimed
CN-114307890-A Bamboo capsule and preparation method and application thereof 中国林业科学研究院木材工业研究所 2022-04-12 — — CN claimed
US-9874566-B2 Compositions and methods for making and using oxygen sensing nanofibers and scaffolds UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2018-01-23 — — US claimed
US-20160041177-A1 COMPOSITIONS AND METHODS FOR MAKING AND USING OXYGEN SENSING NANOFIBERS AND SCAFFOLDS Univ Virginia Patent Found (US) 2016-02-11 — — US claimed
WO-2023064887-A1 MECHANOCHEMICAL DYNAMIC THERAPY FOR FOCAL CANCER TREATMENT THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2023-04-20 — — WO disclosed
US-20230119684-A1 MECHANOCHEMICAL DYNAMIC FOR FOCAL CANCER TREATMENT THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2023-04-20 — — US disclosed
CN-115677739-A Preparation method of O, O-boron difluoride complex 华南理工大学 2023-02-03 — — CN disclosed
CN-114307890-B Bamboo capsule and preparation method and application thereof 中国林业科学研究院木材工业研究所 2022-12-23 — — CN disclosed
CN-114307890-A Bamboo capsule and preparation method and application thereof 中国林业科学研究院木材工业研究所 2022-04-12 — — CN disclosed
US-20180355242-A1 OXYGEN SENSING DIFLUOROBORON B-DIKETONATE POLYLACTIDE MATERIALS FOR WOUND IMAGING NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-12-13 — — US disclosed
US-10149644-B2 Curcumin derivatives for amyloid-β plaque imaging THE GENERAL HOSPITAL CORPORATION (US) 2018-12-11 — — US disclosed
US-9874566-B2 Compositions and methods for making and using oxygen sensing nanofibers and scaffolds UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2018-01-23 — — US disclosed
US-20150087937-A1 CURCUMIN DERIVATIVES FOR AMYLOID-BETA PLAQUE IMAGING MASSACHUSETTS GENERAL HOSPITAL (US) 2015-03-26 — — US disclosed
US-20130210053-A1 MECHANOCHROMIC LUMINESCENT DIFLUOROBORON BETA-DIKETONATES UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2013-08-15 — — US disclosed
US-20110208064-A1 Curcumin Derivatives for Amyloid-Beta Plaque Imaging THE GENERAL HOSPITAL CORPORATION 2011-08-25 — — US disclosed
WO-2011068537-A2 MECHANOCHROMIC LUMINESCENT DIFLUOROBORON BETA-DIKETONATES FRASER CASSANDRA L (US) 2011-06-09 — — WO disclosed
US-7955861-B2 Luminescent diketonate polymers UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2011-06-07 — — US disclosed
WO-2010017094-A2 CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING THE GENERAL HOSPITAL CORPORATION (US) 2010-02-11 — — WO disclosed
US-20090137057-A1 LUMINESCENT DIKETONATE POLYMERS UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2009-05-28 — — US disclosed
WO-2007143209-A2 LUMINESCENT DIKETONATE POLYMERS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2007-12-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150087937-A1 CURCUMIN DERIVATIVES FOR AMYLOID-BETA PLAQUE IMAGING APP, BACE1, PSEN1 KMT2A 2570/4885MEN1 990/4885HPGD 2036/4885
US-10149644-B2 Curcumin derivatives for amyloid-β plaque imaging APP, BACE1, PSEN1 KMT2A 2578/4885MEN1 955/4885HPGD 1971/4885
US-20110208064-A1 Curcumin Derivatives for Amyloid-Beta Plaque Imaging APP, BACE1, PSEN1 KMT2A 2570/4885MEN1 990/4885HPGD 2036/4885
US-20160041177-A1 COMPOSITIONS AND METHODS FOR MAKING AND USING OXYGEN SENSING NANOFIBERS AND SCAFFOLDS ILK, HIF1A, TNNI3 KMT2A 4810/4885MEN1 3310/4885HPGD 905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback